GeneDx Holdings (NASDAQ:WGS) reported fourth-quarter 2025 results on Monday that underscored its successful pivot to a high-margin, "genomic-first" business model.
The Gaithersburg-based leader in rare disease diagnostics delivered $121 million in revenue, hitting the top end of its preliminary estimates and recording a 32% increase in its core exome and genome testing segment.
More significantly, the company achieved adjusted net income of $4.4 million, marking a major step toward sustained profitability.
The quarterly performance was characterized by a sharp acceleration in testing volume, which grew 34% year-over-year.
This growth was driven by deepening penetration into the pediatric and neurology markets, as well as the initial rollout of GeneDx Infinity™, the company’s AI-driven platform that leverages the world's largest rare disease genomic dataset.
Despite the exclusion of a one-time 2024 payer benefit that skewed year-over-year comparisons, the underlying "normalized" growth for the exome and genome business reached an impressive 42%.
"GeneDx is uniquely positioned to deliver for patients, clinicians, and partners—and our results demonstrate that," said CEO Katherine Stueland, who was recently named to the 2026 TIME100 Health list.